| Literature DB >> 22574284 |
Namkee G Choi, Martha L Bruce, Leslie Sirrianni, Mary Lynn Marinucci, Mark E Kunik.
Abstract
Little research has been done on the use of antidepressants among homebound older adults, especially low-income homebound older adults, and their perceptions of the effectiveness of their medication. The purposes of this study were to examine self-reported use of antidepressants among depressed homebound older adults, class and type of antidepressants used, individual-level correlates of antidepressant use, and users' perceptions of the effectiveness of antidepressants. Data on self-reported use of antidepressants were obtained as part of a feasibility study of short-term telehealth problem-solving therapy for depressed low-income homebound adults (n = 162) aged 50 or older. The 24-item Hamilton Rating Scale for Depression (HAMD) was used to assess depression severity. The findings show that about half of the study participants were taking antidepressants, with 26.6% of those on antidepressants rating their medications very effective and 21.5% rating them effective. Female gender was positively, but older age and being Black/African American were negatively associated with the likelihood of antidepressant use. Perceived effectiveness of antidepressants was negatively associated with older age and the HAMD score. The findings suggest that personalized approaches to depression management may be needed in subgroups of depressed older adults, including culturally tailored medication counseling in Black/African-American older adults.Entities:
Keywords: Antidepressant; depression; homebound adults; perceived effectiveness
Year: 2012 PMID: 22574284 PMCID: PMC3345360 DOI: 10.1002/brb3.48
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Participant characteristics (N = 162)
| Sex, | 38 (23.5) |
| Female | 124 (76.5) |
| Age (year) mean ± SD | 65.10 ± 9.57 |
| Range | 50–89 |
| Age group, | |
| 50–59 | 53 (32.7) |
| 60–69 | 61 (37.7) |
| 70–79 | 32 (19.8) |
| 80+ | 16 (9.9) |
| Race/ethnicity, | |
| Non-Hispanic White | 71 (43.8) |
| Blacks/African American | 54 (33.3) |
| Hispanic | 37 (22.8) |
| Education, | |
| <High school | 14 (8.6) |
| Some high school | 23 (14.2) |
| GED or high school graduate | 31 (19.1) |
| Some college | 59 (36.4) |
| 2–4 year college graduate | 22 (13.6) |
| Graduate school attendance or completion | 13 (8.0) |
| Family income, | |
| ≤$15,000 | 113 (69.8) |
| >$15,000 | 49 (30.2) |
| Family support (LSNS-E) | |
| Mean ± SD | 15.77 ± 6.20 |
| Median | 17 |
| Range | 0–28 |
| Health insurance, | |
| Medicare | 129 (79.6) |
| Medicaid | 51 (31.5) |
| Private/VA insurance or MAP | 67 (41.4) |
| No insurance | 4 (2.5) |
| Disability score (WHODAS-II) | |
| Mean ± SD | 35.84 ± 9.03 |
| Median | 36 |
| Range | 13–56 |
| 24-item HAMD score | |
| Mean ± SD | 23.56 ± 7.72 |
| Median | 22.5 |
| Range | 10–42 |
| Depression diagnosis, | |
| Major depressive disorder | 103 (63.6) |
| Depressive disorder-NOS | 53 (32.7) |
| Dysthymic disorder | 6 (3.7) |
| Antidepressant medication currently taking, | |
| Yes, have been taking | 79 (48.8) |
| No, have not been taking | 83 (51.2) |
| Antianxiety medication, currently taking, | |
| Yes, have been taking | 58 (35.8) |
| No, have not been taking | 104 (64.2) |
| Antidepressant/antianxiety medications, | |
| Neither | 64 (39.5) |
| Antidepressant only | 40 (24.7) |
| Antianxiety only | 19 (11.7) |
| Both antidepressant and antianxiety | 39 (24.1) |
| Chronic physical pain during the past 3 months, | |
| Yes, have had pain | 140 (86.4) |
| No, have not had pain | 22 (13.6) |
| Frequency of chronic pain ( | |
| Mean ± SD | 8.66 ± 2.09 |
| Median | 10 |
| Intensity of chronic pain ( | |
| Mean ± SD | 7.69 ± 2.20 |
| Median | 10 |
| Prescription pain medication currently taking, | |
| Yes, have been taking | |
| No, have not been taking | |
Lubben Social Network Scale-Expanded family scale: scores of 0 and 30 represent no family support and full family support, respectively.
World Health Organization Disability Assessment Schedule-II: scores of 12 and 60 represent no disability and extremely severe disability, respectively.
Measured on a 10-point scale (1 = once a week or less often; 10 = all the time).
Measured on a 10-point scale (1 = minimal; 10 = extreme).
Antidepressant class, types, duration of intake, and perceived effectiveness (N = 79)
| No. of antidepressant medication currently taking, | |
| One | 73 (92.4) |
| Two | 6 (7.6) |
| Those taking one antidepressant, | |
| Selective serotonin reuptake inhibitors (SSRIs) | 48 |
| Citalopram | 14 |
| Escitalopram | 9 |
| Fluoxetine | 5 |
| Paroxetine | 3 |
| Sertraline | 17 |
| Serotonin-norepinephrine reuptake inhibitors (SNRIs) | 23 |
| Duloxetine | 13 |
| Mirtazapine | 2 |
| Venlafaxine | 8 |
| Atypical | 2 |
| Buproprion | 2 |
| Those taking two antidepressants, | |
| Citalopram + duloxetine | 1 |
| Citalopram + buproprion | 2 |
| Fluoxetin + duloxetine | 1 |
| Fluoxetin + venlafaxine | 1 |
| Mirtazapine + buproprion | 1 |
| Duration of antidepressant intake ( | |
| Mean | 3.69 ± 4.83 |
| Median | 2.01 |
| Range | 0.2–25.14 |
| Perceived effectiveness of antidepressants, | |
| Very effective | 21 (26.6) |
| Effective | 17 (21.5) |
| Somewhat effective | 21 (26.6) |
| A little effective | 5 (6.3) |
| Not effective | 1 (1.3) |
| Do not yet know/cannot tell without getting off | 14 (17.7) |
Thirteen subjects could not recall when they had begun taking antidepressants.
Correlates of antidepressant intake: binary logistic regression results (N = 162)
| Variable | B (SE) | Odds ratio (95% CI) |
|---|---|---|
| Sex | ||
| Female | 1.10 (0.50) | 3.0 (1.12–8.05) |
| (Male) | ||
| Age group | ||
| (50–59) | ||
| 60–69 | −0.56 (0.49) | 0.57 (0.22–1.48) |
| 70+ | −1.61 (0.55) | 0.20 (0.07–0.59) |
| Race/ethnicity | ||
| (Non-Hispanic White) | ||
| Black/African American | −1.85 (0.49) | 0.16 (0.06–0.41) |
| Hispanic | −0.36 (0.49) | 0.70 (0.27–1.81) |
| Education | ||
| High school or lower | 0.37 (0.42) | 1.45 (0.63–3.33) |
| (at least some college) | ||
| Income | ||
| ≤$15,000 | −0.10 (0.45) | 0.37 (0.15–0.92) |
| (>$15,000) | ||
| Private/veterans insurance or MAP | ||
| Yes | 0.55 (0.41) | 1.72 (0.77–3.87) |
| (No) | ||
| Family support score | 0.02 (0.03) | 0.98 (0.92–1.05) |
| Disability score (WHODAS-II) | 0.01 (0.03) | 1.01 (0.96–1.06) |
| 24-item HAMD score | −0.02 (0.03) | 0.98 (0.93–1.03) |
| Antianxiety medication | ||
| Yes | 1.28 (0.41) | 3.59 (1.60–8.07) |
| (No) | ||
| Prescription pain medication | ||
| Yes | 0.53 (0.41) | 1.70 (0.76–3.80) |
| (No) | ||
| Cox & Snell | 0.27 | |
| Nagelkerke | 0.37 | |
| −2 log-likelihood model χ2 (df, | 172.72 (13; |
P < 0.001
P < 0.01
P < 0.05.